Citations

Clear

4206 citation(s) found for "Chen, Yu".

Ultrasound stimulated vibrometry for measuring tissue properties
Greenleaf, James F. , Chen, Shigao , Zhang, Xiaoming

Mayo Clinic

The Journal of the Acoustical Society of America | May 12, 2008 | Volume: 123 | Issue: 5_Supplement | Pages: 3791-3791

10.1121/1.2935456 Get It

Harmonic or pulsed radiation pressure and subsequent measurement of the tissue response can be used to accurately quantitatively measure fundamental material properties of tissue. The measurement of shear wave dispersion can be used to estimate elastic shear moduli of tissue using an appropriate model. Fundamental model free properties such as complex modulus can also be measured. Ultrasound radiation pressure is used to induce free propagating shear waves. The measurable properties of the shear waves such as speed are sensitive to only the local material properties of the tissue under certain circumstances. A model relating the shear wave speed as a function of frequency is related to the elastic and viscous moduli within small regions of tissue according to, for instance, the Voigt model. Shear and elastic moduli in tissue are measured with high accuracy and precision given appropriate models of wave propagation within the geometry of the tissue. Complex modulus in liver of live pig and other tissues have been made. Careful use of shear wave propagation and subsequent measurements can provide fundamental quantitative measurements of tissue mechanical properties if models are accurate. An application of this method is the noninvasive measurement of liver stiffness as a surrogate for fibrosis.
Bile Acid Exposure Up-regulates Tuberous Sclerosis Complex 1/Mammalian Target of Rapamycin Pathway in Barrett's-Associated Esophageal Adenocarcinoma
Yen, Chia-Jui , Izzo, Julie, Lee, Dung‐Fang , Guha, Sushovan , Wei, Yongkun , Wu, Tsung‐Teh, Kuo, Hsu-Ping, Hsu, Jung-Mao , Sun, Hui-Lung, Chou, Chao‐Kai , Buttar, Navtej , Wang, Kenneth K. , Huang, Peng , Hung, Mien‐Chie , Chen, Chun‐Te , Kuo, Hsu-Ping, Ajani, Jaffer A.

Mayo Clinic

Cancer Research | April 15, 2008 | Volume: 68 | Issue: 8 | Pages: 2632-2640

10.1158/0008-5472.can-07-5460 | PMID 18413730 Get It

Abstract Barrett's esophagus, a columnar metaplasia of the lower esophagus epithelium related to gastroesophageal reflux disease, is the strongest known risk factor for the development of esophageal adenocarcinoma (EAC). Understanding the signal transduction events involved in esophageal epithelium carcinogenesis may provide insights into the origins of EAC and may suggest new therapies. To elucidate the molecular pathways of bile acid–induced tumorigenesis, the newly identified inflammation-associated signaling pathway involving IκB kinases β (IKKβ), tuberous sclerosis complex 1 (TSC1), and mammalian target of rapamycin (mTOR) downstream effector S6 kinase (S6K1) was confirmed to be activated in immortalized Barrett's CPC-A and CPC-C cells and esophageal cancer SEG-1 and BE3 cells. Phosphorylation of TSC1 and S6K1 was induced in response to bile acid stimulation. Treatment of these cells with the mTOR inhibitor rapamycin or the IKKβ inhibitor Bay 11-7082 suppressed bile acid–induced cell proliferation and anchorage-independent growth. We next used an orthotopic rat model to evaluate the role of bile acid in the progression of Barrett's esophagus to EAC. Of interest, we found high expression of phosphorylated IKKβ (pIKKβ) and phosphorylated S6K1 (pS6K1) in tumor tissues and the Barrett's epithelium compared with normal epithelium. Furthermore, immunostaining of clinical EAC tissue specimens revealed that pIKKβ expression was strongly correlated with pS6K1 level. Together, these results show that bile acid can deregulate TSC1/mTOR through IKKβ signaling, which may play a critical role in EAC progression. In addition, Bay 11-7082 and rapamycin may potentially be chemopreventive drugs against Barrett's esophagus–associated EAC. [Cancer Res 2008;68(8):2632–40]
Toll-like Receptor Polymorphisms and Age-Related Macular Degeneration
Edwards, Albert O., Chen, Dequan , James, Katherine M. , Wu, Yanhong , Abecasis, Gonçalo R. , Swaroop, Anand , Othman, Mohammad , Branham, Kari , Iyengar, Sudha K. , Sivakumaran, Theru A. , Klein, Ronald , Klein, Barbara E.K. , Tosakulwong, Nirubol , Fridley, Brooke L. , Abecasis, Gonçalo

Mayo Clinic

Investigative Opthalmology & Visual Science | April 1, 2008 | Volume: 49 | Issue: 4 | Pages: 1652

10.1167/iovs.07-1378 | PMID 18385087 Get It

A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension
Oparil, Suzanne , Abate, Nicola , Chen, E., Galet, Vincent A., Jia, Gang , Julius, Stevo, Lerman, A., Lyle, Paulette A., Pool, James L., Tershakovec, Andrew M. , Creager, Mark A.

Mayo Clinic

Current Medical Research and Opinion | March 8, 2008 | Volume: 24 | Issue: 4 | Pages: 1101-1114

10.1185/030079908x280716 | PMID 18328120 Get It

Impact of Restricting Enrollment in Stroke Genetics Research to Adults Able to Provide Informed Consent
Chen, Donna T. , Case, L. Douglas, Brott, Thomas G. , Brown, Robert D., Silliman, Scott, Worrall, Bradford B. , Meschia, James F.

Mayo Clinic

Stroke | February 8, 2008 | Volume: 39 | Issue: 3 | Pages: 831-837

10.1161/strokeaha.107.494518 | PMID 18258838 Get It

Background and Purpose— The extent of potential consent bias in observational studies elucidating genetic and environmental contributions to ischemic stroke is largely unknown. The purpose of this study was to assess differences in stroke cohort characteristics between those who provided informed consent and those whose enrollment was authorized by surrogate decision makers. Methods— The Ischemic Stroke Genetics Study (ISGS) is a prospective, 5-center, case-control study of first-ever ischemic stroke. Demographic, clinical, and stroke characteristics were compared between cases enrolled by self versus by surrogate. Data from one site that limits enrollment only to those able to self-consent were also analyzed to compare those who enrolled with those not able to consent. Results— Overall, 10% (54 of 517) were enrolled using surrogate authorization. Self-consented and surrogate-authorized cases did not differ significantly in age, sex, or conventional risk factors. Surrogate-authorized cases had significantly more severe stroke deficits, larger infarcts, and infarcts localizing to left supratentorial regions. Similarly, at the site restricting enrollment, stroke severity and characteristics differed between self-consented individuals and those otherwise eligible but unable to provide consent. Conclusions— Failure to permit surrogate authorization in genetic studies of ischemic stroke may skew enrollment toward less severe strokes caused by smaller infarcts. This potential consent bias may undermine the ability to identify genetic determinants of risk and severity and suggests that surrogate enrollment in these studies can be ethically justifiable.
Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study
Bender, Julia Glade , Adamson, Peter C. , Xu, Lu , Baruchel, Sylvain , Kerbel, Robert S. , Cooney-Qualter, Erin, Stempak, Diana, Chen, Helen X., Nelson, Marvin D. , Krailo, Mark , Ingle, Ashish M., Blaney, Susan M. , Kandel, Jessica J. , Reid, Joel M. , Shaked, Yuval , Yamashiro, Darrell J. , Glade-Bender, Julia

Mayo Clinic

Journal of Clinical Oncology | January 17, 2008 | Volume: 26 | Issue: 3 | Pages: 399-405

10.1200/jco.2007.11.9230 | PMID 18202416 Get It

Purpose We conducted a pediatric phase I trial of the vascular endothelial growth factor (VEGF)–neutralizing antibody bevacizumab (BV). Primary aims included estimating the maximum-tolerated dose (MTD) and determining the dose-limiting toxicities (DLTs), pharmacokinetics, and biologic effects of BV in children with cancer. Patients and Methods BV (5, 10, 15 mg/kg) was administered intravenously every 2 weeks in 28-day courses to children with refractory solid tumors. Results Twenty-one patients enrolled, 20 (median age, 13 years) were eligible, and 18 completed one course and were fully assessable for toxicity. A total of 67 courses were administered (median, three courses per patient; range, one to 16 courses). Treatment was well tolerated with no DLTs observed. Non-DLTs included infusional reaction, rash, mucositis, proteinuria, and lymphopenia. Increases in systolic and diastolic blood pressure not meeting Common Terminology Criteria for Adverse Events (CTCAEv3) pediatric-specific criteria for hypertension were observed. There was no hemorrhage or thrombosis. Growth perturbation was not detected in a limited sample over the first course. The serum exposure to BV as measured by area under the concentration-time curve (AUC) seemed to increase in proportion to dose. The median clearance of BV was 4.1 mL/d/kg (range, 3.1 to 15.5 mL/d/kg), and the median half-life was 11.8 days (range, 4.4 to 14.6 days). No objective responses were observed. Exploratory analyses on circulating endothelial mobilization and viability are consistent with the available adult data. Conclusion BV is well tolerated in children. Phase II pediatric studies of BV in combination with chemotherapy in dosing schedules similar to adults are planned.
Cysteines Flanking the Internal Fusion Peptide Are Required for the Avian Sarcoma/Leukosis Virus Glycoprotein To Mediate the Lipid Mixing Stage of Fusion with High Efficiency
Delos, Sue E., Brecher, Matthew , Chen, Zaoying, Melder, Deborah C., Federspiel, Mark J. , White, Judith M.

Mayo Clinic

Journal of Virology | January 10, 2008 | Volume: 82 | Issue: 6 | Pages: 3131-3134

10.1128/jvi.02266-07 | PMID 18184714 Get It

ABSTRACT We previously showed that the cysteines flanking the internal fusion peptide of the avian sarcoma/leukosis virus subtype A (ASLV-A) Env (EnvA) are important for infectivity and cell-cell fusion. Here we define the stage of fusion at which the cysteines are required. The flanking cysteines are dispensable for receptor-triggered membrane association but are required for the lipid mixing step of fusion, which, interestingly, displays a high pH onset and a biphasic profile. Second-site mutations that partially restore infection partially restore lipid mixing. These findings indicate that the cysteines flanking the internal fusion peptide of EnvA (and perhaps by analogy Ebola virus glycoprotein) are important for the foldback stage of the conformational changes that lead to membrane merger.
Mutation of an A-kinase-anchoring protein causes long-QT syndrome
Marquardt, Michelle L., Tester, David J. , Sampson, Kevin J. , Ackerman, Michael J. , Kass, Robert S. , Chen, Lei

Mayo Clinic

Proceedings of the National Academy of Sciences | December 19, 2007 | Volume: 104 | Issue: 52 | Pages: 20990-20995

10.1073/pnas.0710527105 | PMID 18093912 Get It

A-kinase anchoring proteins (AKAPs) recruit signaling molecules and present them to downstream targets to achieve efficient spatial and temporal control of their phosphorylation state. In the heart, sympathetic nervous system (SNS) regulation of cardiac action potential duration (APD), mediated by β-adrenergic receptor (βAR) activation, requires assembly of AKAP9 (Yotiao) with the I Ks potassium channel α subunit (KCNQ1). KCNQ1 mutations that disrupt this complex cause type 1 long-QT syndrome (LQT1), one of the potentially lethal heritable arrhythmia syndromes. Here, we report identification of ( i ) regions on Yotiao critical to its binding to KCNQ1 and ( ii ) a single putative LQTS-causing mutation (S1570L) in AKAP9 (Yotiao) localized to the KCNQ1 binding domain in 1/50 (2%) subjects with a clinically robust phenotype for LQTS but absent in 1,320 reference alleles. The inherited S1570L mutation reduces the interaction between KCNQ1 and Yotiao, reduces the cAMP-induced phosphorylation of the channel, eliminates the functional response of the I Ks channel to cAMP, and prolongs the action potential in a computational model of the ventricular cardiocyte. These reconstituted cellular consequences of the inherited S1570L-Yotiao mutation are consistent with delayed repolarization of the ventricular action potential observed in the affected siblings. Thus, we have demonstrated a link between genetic perturbations in AKAP and human disease in general and AKAP9 and LQTS in particular.
SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma
Monti, Stefano , Juszczyński, Przemysław , Daley, John, Chen, Wen , Kutok, Jeffery L. , Chen, Lin‐Feng , Witzig, Thomas E. , Habermann, Thomas M. , Shipp, Margaret Ann

Mayo Clinic

Blood | November 15, 2007 | Volume: 111 | Issue: 4 | Pages: 2230-2237

10.1182/blood-2007-07-100115 | PMID 18006696 Get It

The role of B-cell receptor (BCR)–mediated survival signals in diffuse large B-cell lymphoma (DLBCL) remains undefined. Ligand-induced BCR signaling induces receptor oligomerization, Igα/β immunoreceptor tyrosine-based activation motif (ITAM) phosphorylation, and activation of the spleen tyrosine kinase (SYK), which initiates downstream events and amplifies the initial BCR signal. BCRs also transmit low-level tonic survival signals in the absence of receptor engagement. Herein, we assess the role of SYK-dependent tonic BCR survival signals in DLBCL cell lines and primary tumors and evaluate the efficacy of an ATP-competitive inhibitor of SYK, R406, in vitro. R406 induced apoptosis of the majority of examined DLBCL cell lines. In R406-sensitive DLBCL cell lines, R406 specifically inhibited both tonic- and ligand-induced BCR signaling (autophosphorylation of SYK525/526 and SYK-dependent phosphorylation of the B-cell linker protein [BLNK]). The majority of examined primary DLBCLs also exhibited tonic- and ligand-induced BCR signaling; in these primary tumors, BCR signaling was also inhibited by R406. Of note, BCR-dependent and R406-sensitive DLBCL cell lines were independently identified as “BCR-type” tumors by transcriptional profiling. Therefore, SYK-dependent tonic BCR signaling is an important and potentially targetable survival pathway in some, but not all, DLBCLs. In addition, R406-sensitive DLBCLs can be identified by their transcriptional profiles.
Dynamin 2 mediates fluid-phase micropinocytosis in epithelial cells
Cao, Hong , Awoniyi, Muyiwa , Henley, John R. , McNiven, Mark A. , Chen, Jing

Mayo Clinic

Journal of Cell Science | November 15, 2007 | Volume: 120 | Issue: 23 | Pages: 4167-4177

10.1242/jcs.010686 | PMID 18003703 Get It

It is well-known that dynamin 2 (Dyn2) participates in clathrin- and caveolae-mediated endocytosis; however, the role of Dyn2 in coat-independent endocytic processes remains controversial. Here we demonstrate a role for specific spliced variants of Dyn2 in the micropinocytosis of fluid in epithelial cells, independent of coat-mediated endocytic pathways. A general inhibition of Dyn2 was first performed using either microinjection of anti-dynamin antibodies or Dyn2-siRNA treatment. Both of these methods resulted in reduced uptake of transferrin, a marker for clathrin-mediated endocytosis, and, under unstimulated conditions, reduced the uptake of the fluid-phase markers dextran and horseradish peroxidase (HRP). By contrast, cells treated similarly but stimulated with serum or EGF internalized substantial amounts of dextran or HRP, indicating that Dyn2 is not required for stimulated fluid uptake via macropinocytosis. We next tested whether a specific spliced variant might selectively affect fluid-phase endocytosis. Mutation of specific Dyn2 spliced variants resulted in a differential attenuation of transferrin and dextran internalization. Furthermore, the reduction in fluid uptake in Dyn2-siRNA-treated cells was only rescued upon re-expression of select spliced variants. These findings suggest that Dyn2 function is required for the coat-independent internalization of fluid through endocytic pathways distinct from macropinocytosis and, in addition, implicate different Dyn2 spliced variants in specific endocytic functions.